EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ocular Therapeutix's Enterprise Value is $1,649.44 Mil.
Ocular Therapeutix's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-240.94 Mil. Therefore, Ocular Therapeutix's EV-to-FCF for today is -6.85.
The historical rank and industry rank for Ocular Therapeutix's EV-to-FCF or its related term are showing as below:
OCUL'
s EV-to-FCF Range Over the Past 10 Years
Min: -27.47 Med: -4.74 Max: -1.04
Current: -6.85
During the past 13 years, the highest EV-to-FCF of Ocular Therapeutix was -1.04. The lowest was -27.47. And the median was -4.74.
OCUL's EV-to-FCF is ranked worse than 100% of 329
companies
in the Biotechnology industry
Industry Median: 15.85
vs OCUL: -6.85
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ocular Therapeutix's PE Ratio (TTM) for today is calculated as:
Ocular Therapeutix's share price for today is $10.215.
Ocular Therapeutix's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.460.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Ocular Therapeutix EV-to-FCF Related Terms
Ocular Therapeutix EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Ocular Therapeutix's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ocular Therapeutix's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocular Therapeutix EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ocular Therapeutix's EV-to-FCF falls into.
Ocular Therapeutix's current Enterprise Value is $1,649.44 Mil.
Ocular Therapeutix's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-240.94 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocular Therapeutix (OCUL) has a EV-to-FCF of -6.85 as of Jul. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ocular Therapeutix and its competitors. According to the industry distribution chart, Ocular Therapeutix ranks #999999 out of 329 companies in the Biotechnology industry.
Is Ocular Therapeutix's EV-to-FCF too high?
Ocular Therapeutix's current EV-to-FCF is -6.85. Based on the distribution chart, Ocular Therapeutix ranks #999999 out of 329 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ocular Therapeutix has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ocular Therapeutix's EV-to-FCF compare to NKTR and PVLA?
According to the Biotechnology industry distribution chart, Ocular Therapeutix ranks #999999 out of 329 companies for EV-to-FCF. This places Ocular Therapeutix in the lower half of its industry. The industry median EV-to-FCF is 15.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.85, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ocular Therapeutix and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocular Therapeutix's current EV-to-FCF is -6.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocular Therapeutix stock overvalued right now?
Based on GuruFocus' analysis, Ocular Therapeutix (OCUL) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.38, compared to a current price of $10.22 — trading 133.2% above its estimated fair value. The current EV-to-FCF is -6.85. Ocular Therapeutix's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Ocular Therapeutix (OCUL), the current EV-to-FCF is -6.85 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocular Therapeutix (OCUL) Overvalued in 2026?
Based on GuruFocus' analysis, Ocular Therapeutix stock appears to be overvalued.
The current stock price of $10.22 is trading 133.2% above its estimated GF Value™ of $4.38.
GuruFocus considers Ocular Therapeutix to be Significantly Overvalued.
Key valuation signals for OCUL:
EV-to-FCF: -6.85
GF Value™: $4.38 vs. price of $10.22 (133.2% above fair value)
No single metric tells the full story. See the OCUL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
51GF Score
Get the complete analysis for OCUL
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCUL has been successfully added to your 
